Zobrazeno 1 - 10
of 372
pro vyhledávání: '"Yongheng, Chen"'
Publikováno v:
Cell Death and Disease, Vol 15, Iss 3, Pp 1-13 (2024)
Abstract Activation of the Hippo pathway by angiomotins to limit colorectal cancer progression is prevalent, whereas the regulation of angiomotins remains elusive. In this study, we uncover the involvement of an upregulated E3 ubiquitin ligase called
Externí odkaz:
https://doaj.org/article/aa4ec993daf944a2b18b367d4133b5bb
Autor:
Qianmeng Lin, Shuyan Dai, Lingzhi Qu, Hang Lin, Ming Guo, Hudie Wei, Yongheng Chen, Xiaojuan Chen
Publikováno v:
Communications Chemistry, Vol 7, Iss 1, Pp 1-9 (2024)
Abstract Acquired drug resistance poses a challenge for single-target FGFR inhibitors, leading to the development of dual- or multi-target FGFR inhibitors. Sulfatinib is a multi-target kinase inhibitor for treating neuroendocrine tumors, selectively
Externí odkaz:
https://doaj.org/article/dcafca7f8809436ea954478d3121cab2
Publikováno v:
Cell Death and Disease, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Nasopharyngeal carcinoma (NPC) is a malignant tumor that is highly prevalent in Southeast Asia, especially in South China. The pathogenesis of NPC is complex, and genetic alterations of tumor suppressors and proto-oncogenes play important ro
Externí odkaz:
https://doaj.org/article/7f90a08851424de9b45bded3b3b7cdd3
Publikováno v:
iScience, Vol 27, Iss 4, Pp 109377- (2024)
Summary: Glycemic and body weight control gained from GLP-1R agonists remains an unmet need for diabetes and obesity treatment, leading to the development of GLP-1R/GIPR co-agonists. An imbalance in GLP-1R/GIPR agonism may extensively maximize the gl
Externí odkaz:
https://doaj.org/article/37c937afba7b458e9aea73941400d924
Publikováno v:
iScience, Vol 27, Iss 1, Pp 108645- (2024)
Summary: Aerobic glycolysis is a pivotal hallmark of cancers, including colorectal cancer. Evidence shows glycolytic enzymes are regulated by post-translational modifications (PTMs), thereby affecting the Warburg effect and reprograming cancer metabo
Externí odkaz:
https://doaj.org/article/87ee795f774e4398b0bcb0ea531665b2
Autor:
Hudie Wei, Haolan Wang, Genxin Wang, Lingzhi Qu, Longying Jiang, Shuyan Dai, Xiaojuan Chen, Ye Zhang, Zhuchu Chen, Youjun Li, Ming Guo, Yongheng Chen
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Mitochondrial apoptosis is strictly controlled by BCL-2 family proteins through a subtle network of protein interactions. The tumor suppressor protein p53 triggers transcription-independent apoptosis through direct interactions with BCL-2 fa
Externí odkaz:
https://doaj.org/article/db48de5db5fe4d37941c8b75ef220bd1
Publikováno v:
European Journal of Medical Research, Vol 28, Iss 1, Pp 1-15 (2023)
Abstract Background Necroptosis has been reported to play a critical role in occurrence and progression of cancer. The dysregulation of long non-coding RNAs (lncRNAs) is associated with the progression and metastasis of clear cell renal cell carcinom
Externí odkaz:
https://doaj.org/article/d75e33f03c0b4cac9bc152686d00e988
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-35 (2023)
Abstract The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has been a major focus of oncology research. The p53 protein is a transcription factor that can activate the expression of multiple target genes and plays cr
Externí odkaz:
https://doaj.org/article/2b55487f2fd8482d833c6b842c8a4759
Publikováno v:
Biomarker Research, Vol 11, Iss 1, Pp 1-20 (2023)
Abstract The Maf proteins (Mafs) belong to basic leucine zipper transcription factors and are members of the activator protein-1 (AP-1) superfamily. There are two subgroups of Mafs: large Mafs and small Mafs, which are involved in a wide range of bio
Externí odkaz:
https://doaj.org/article/7d54044e248649bd8505315ccd2767d3
Autor:
Lingzhi Qu, Hang Lin, Shuyan Dai, Ming Guo, Xiaojuan Chen, Longying Jiang, Huajun Zhang, Maoyu Li, Xunjun Liang, Zhuchu Chen, Hudie Wei, Yongheng Chen
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 21, Iss , Pp 5712-5718 (2023)
c-Met has been an attractive target of prognostic and therapeutic studies in various cancers. TPX-0022 is a macrocyclic inhibitor of c-Met, c-Src and CSF1R kinases and is currently in phase I/II clinical trials in patients with advanced solid tumors
Externí odkaz:
https://doaj.org/article/ce007b844e0342e383a6ce6b5925beef